<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359930</url>
  </required_header>
  <id_info>
    <org_study_id>NaltrexoneBupropion-Ph1A-met</org_study_id>
    <nct_id>NCT01359930</nct_id>
  </id_info>
  <brief_title>Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study</brief_title>
  <official_title>Phase 1 Study of Interactions Between Oral Naltrexone and Bupropion and Intravenous Methamphetamine in Methamphetamine Experienced Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The study is to primarily measure safety and interactions between oral doses of
      Naltrexone/Bupropion and i.v. Methamphetamine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular System Effects</measure>
    <time_frame>daily during the 10 day treatment period</time_frame>
    <description>Heart rate, blood pressure, ECGs,and monitoring adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Day 0 through Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations obtained at specific timepoints</measure>
    <time_frame>daily during the 10 day treatment period</time_frame>
    <description>PK of IV (meth) and its metabolites before and during Naltrexone/BUP exposure
PK of bupropion, naltrexone and their metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Vital Signs and Clinical Chemistries</measure>
    <time_frame>Daily during the 10 day treatment period</time_frame>
    <description>Respiration rate and clinical laboratory measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Assessments as reported by the subject</measure>
    <time_frame>Dailly during the 10 day treatment period</time_frame>
    <description>Subject reported effects measured with VAS, BSCS, and POMS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone and Bupropion SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and Bupropion SR</intervention_name>
    <description>25mg bid/day (NX) 200mg bid/day (BUP)</description>
    <arm_group_label>Naltrexone and Bupropion SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are MA experienced but not dependent, males or females aged 21-to-50 years.

          -  Reported use of MA during the past six months without experiencing an adverse
             consequence plus a life time MA or amphetamine use history of at least four occasions
             of use.

          -  Have a body mass index (BMI) between 18 and 30.

          -  Are willing and able to give written consent.

          -  Are not currently a subject (including still in the follow-up period) of another drug
             research study.

          -  Have no medical contraindications determined by the following: an adequate medical
             history, a physical examination including vital signs, 12-lead ECG, hematology, blood
             chemistry, and urinalysis.

          -  Have a negative drug test for barbiturates, benzodiazepines, opiates, cocaine,
             amphetamines and ethanol at the time of hospital admission (Day 0).

          -  Are females who have a negative pregnancy test at hospital admission.

          -  Are of either non-childbearing (tubal ligation or total hysterectomy) or of
             childbearing potential using one or more of the following barrier methods of
             contraception: male or female condoms (with/without spermicide), diaphragm (with
             spermicide) and/or copper containing intrauterine device (with/without spermicide). No
             other contraceptives are acceptable.

        Exclusion Criteria:

          -  Please contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Langley Porter Psychiatric Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Bupropion hydrochloride, naltrexone hydrochoride drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

